32nd Pharmacovigilance 2023

32nd Pharmacovigilance 2023

26th & 27th April 2023, The Conference Center at Waltham Woods, Waltham, (Boston, USA)

32nd Pharmacovigilance 2023 event will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. Get more from the event, with a broader scope bringing the whole communications value chain together.

Please contact Kavitha at E-mail - kavitha@virtueinsight.co.in   or call +44 20 3509 3779

DELEGATE REGISTRATION:

STANDARD PRICE

1 Delegate @ $1699

Group Discount @ $3398 (3 Delegates for the price of 2)

SPONSORS:

Pharsafer, Qinecsa Solutions, EDGYN, Arisglobal

We have sponsorship opportunities available for the event, which gives you an opportunity to speak/exhibit, and create brand awareness.  Here you can have a dedicated networking time, meet the leading international vendors and expand your knowledge of the latest business models. Please email to kavitha@virtueinsight.co.in   for more details.

KEY SPEAKERS:

• KHAUDEJA BANO, Vice President, Combination Product Quality, Amgen
• BRUNO MENDEZ, VP Global Quality Head Pharmacovigilance, Sanofi
• MARIETTE BOERSTOEL-STREEFLAND, SVP Patient Safety, Chief Safety Officer, Alexion Pharmaceuticals
• JEREMY JOKINEN, VP Global Risk Management & International Patient Safety, Bristol-Myers Squibb
• CARMIT STRAUSS, Executive Director, Head of Risk Management and Organ Toxicity, Takeda Pharmaceuticals
• SHARON REID, Director, Risk Management Product Lead, Pfizer
• RENA PANDIT, Executive Director, Global Patient Safety Head of PV Compliance & Training, Amgen
• AYSE BAKER, Vice President of Regulatory Affairs, Almatica (Alvogen)
• HUMAIRA QURESHI, President, Qinecsa Solutions
• MARITESS ESGUERRA, Senior PV Process Director, Genentech
• JAYLAXMI NALAWADE, Associate Director - Pharmacovigilance and REMS, Lupin
• DEEPA VENKATARAMAN, Vice President, Head of Drug Safety and PV, Corcept Therapeutics
• KANAN BHAVSAR, Medical Director, Pharmacovigilance, Deciphera Pharmaceuticals
• SHEETAL KHEDKAR, Deputy Therapeutic Area Safety Head, ED, Johnson & Johnson
• GRAEME LADDS, CEO, PharSafer
• MARCIN VON GROTTHUSS, Principal Scientist, Investigative Toxicology, Takeda Pharmaceuticals
• KAL ELHOREGY, Director, Risk Evaluation & Mitigation Strategy (REMS) Programs, Amneal Pharmaceuticals
• NANCY DUBOIS, Head of Global Patient Safety US, Merck-EMD Serono
• NISHITH JOBANPUTRA, Disease Area Cluster Lead, Worldwide Safety, Pfizer
• CAMILLE DISS, CPO, EDGYN
• BEN LOCWIN, Executive SME, Black Diamond Networks
• ADEL ABOU-ALI, Head of Benefit Risk Center of Excellence (CoE), GPSE, Takeda
• BILL HADDOCK, VP Pharmacovigilance & GXP Quality, Ovid Therapeutics
• AJINKYA INAMDAR, Senior Director (Global Medical Safety Strategy), BioNTech SE
• TEODORA DOHERTY, Global Medical Safety (GMS), Medical Safety Officer, Janssen Research & Development
• LINA OGBU, Medical Director Drug Safety & Pharmacovigilance, Arcus biosciences
• STEPHEN F. AMATO, Director, Global Regulatory Affairs & Quality Assurance Programs, Northeastern University
• JERRY K. KOUNGA, Investigational Drug Lead Clinical Research Pharmacist, Ascension Wisconsin Research Institute
• KAPIL BHUTADA, Director, Pharmacovigilance Compliance & Training, Medicago
• ELIZABETH BAKER, Associate Professor, Virginia Commonwealth University
• BENJAMIN BROWN, Executive Director, American Society of Pharmacovigilance
• JESSICA VAUGHN, Attorney at Law, Wiley Rein

Plus more joining soon

FOCUSES ON

• Pharmacovigilance: What comes next for the PV industry?
• Challenges and opportunities for better future of Pharmacovigilance
• Outsourcing - Best Practices, Challenges & key consideration in choosing right vendor
• Proper communication between - Sponsor – Site – CRO – Patients
• Quality, Safety & Signal Detection – Best practice
• Modern Technologies in Pharmacovigilance - The Way Forward
• Automation in Pharmacovigilance: A Closer look at use cases
• Prioritising patients – Ensuring patient safety first
• Next generation pharmacovigilance for enhanced patient safety
• PV operations within financial and logistical constraints
• Risk Management – Proper plans for a perfect tomorrow
• Why does pharmacovigilance sometimes fail and where could the fault lie?
• Managing Pharmacovigilance Audits & Inspections
• The developing regulatory framework in advanced and developing markets
• Boldly shaping the future
• Best practices and lessons learnt from the pandemic
• Be part of a major networking opportunity

WHO SHOULD ATTEND

CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:

Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales and Marketing

Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.